I've been researching Geron's patent position on telomerase lately. Along the way, I discovered there divestiture of the stem cell assests.....which included granted & pending patents. Further research uncovered the actual agreement (which detailed the patent numbers) between GERN and BTX in early 2013. I summarized the list of those transferred to BTX in order to 'net them out' of GERN's current patent portfolio. Upon reading your note, I searched for 'nuclear' within the US granted patents transferred to BTX and my findings are listed below. I hope this info is of interest/use to you.
US7402307 and US6440735 contain the term 'mononuclear' within the claim sets.
US6506574 contains the term 'nuclear' within its claim set.
FYI....You can obtain the above publications via Google patents.
FYI.....US20090137040 is now shown as abandoned at USPTO....resulting from the applicant's failure to respond to an office action. It was rejected by USPTO as unpatentable based on prior art which included US6235970, US7951591, US6194202, and US5945577.
An amusing point. Of course they have to pay to defend the patents they did get---which are already under attack.
As I said when the LOI was done, BTX was getting about $165mm in GERN i/p for about $6mm...People in the industry tell me that was about $3mm too much, given results so far.